Ascelia Pharma (STO:ACE) confirmed in its first-quarter report that its liver imaging agent Orviglance remains on track for a US Food and Drug Administration decision by its July 3, 2026, target date.
"Orviglance® is on track for approval on the July 3 PDUFA date. FDA's review of our New Drug Application (NDA) progressed as planned during the quarter, and we remain fully engaged in a constructive, transparent dialogue with the agency," Magnus Corfitzen, CEO at Ascelia Pharma, said in a statement.
The Swedish biotech company's NDA is based on a development program of nine clinical studies. The pivotal Phase 3 SPARKLE study showed Orviglance significantly improved visualization of focal liver lesions in patients with impaired kidney function, meeting the primary endpoint for all three readers. Following the quarter's end, the company raised SEK 20 million through a directed share issue to bolster its negotiating position for commercial partnerships.
An FDA approval represents a major milestone for Ascelia, which focuses on orphan oncology treatments. The additional capital from the April share issue extends the company's cash runway into 2027, providing flexibility as it engages in multiple discussions with potential commercial partners. The company ended the first quarter with liquid assets of SEK 33.9 million.
In its Q1 2026 report, Ascelia posted an operating result of SEK -17.2 million and earnings per share of SEK -0.13. The company also noted that an abstract featuring Orviglance data was accepted for an oral presentation at the annual European Society of Gastrointestinal and Abdominal Radiology (ESGAR) congress in 2026, adding to the drug's scientific validation.
The upcoming PDUFA date is the next major catalyst for the company. A positive FDA decision would be a significant value inflection point, enabling the commercial launch of Orviglance in a key market.
This article is for informational purposes only and does not constitute investment advice.
